ReviewNature reviews. Disease primers2023
Hepatitis A virus infection.
Review in Nature reviews. Disease primers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Evolution and Impact of Hepatitis A Epidemiology in Europe-Systematic Literature Review of the Last 20 Years.Journal of viral hepatitis · 2025Pooled it
- Examining the changes in the prevalence of Hepatitis a in Türkiye: systematic review and metaanalysis.BMC public health · 2024Pooled it
- Long-term protection from naturally acquired immunity against hepatitis E virus reinfection.Nature communications · 2025Trial
- Phytochemical profile and in vitro antimicrobial, antiviral, and anticancer activities of Echium angustifolium ethanolic extract.Scientific reports · 2026Article
- Global landscape of liver disease burden in 1990-2021.iScience · 2026Article
- CD8MedComm · 2026Review
- Prevalence of Viral Hepatitis in Three Public Health Clinics in the Kingston Metropolitan Area, Jamaica, 2022.The American journal of tropical medicine and hygiene · 2026Article
- Hepatocyte BDNF Acts as a Novel Immune Checkpoint to Restrain TLR4-Mediated Acute Hepatitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- From hepatitis A to acute liver failure in a resource-limited setting: a case report.IJID regions · 2026Article
- Single-Center Retrospective Study of Hospitalized Hepatitis A Cases in Southern Bulgaria, 2015-2023.Healthcare (Basel, Switzerland) · 2026Article
- Azathioprine Inhibits Hepatitis A Virus Replication In Vitro.Pathogens (Basel, Switzerland) · 2026Article
- Epidemiology of hepatitis A in Saudi Arabia: a retrospective analysis of Ministry of Health surveillance and yearbook data, 2006-2023.Frontiers in epidemiology · 2026Article
- Viral emergence and pandemic preparedness in a One Health framework.Nature reviews. Microbiology · 2026Review
- An engineered human hepatitis A virus capable of rapid proliferationJHEP reports : innovation in hepatology · 2025Article
- Expert consensus and recommendations on the live attenuated hepatitis A vaccine and immunization practices in India.Human vaccines & immunotherapeutics · 2025Article
- Natural killer cells and IFN-γ protect against liver injury during HAV infection in mice.Journal of virology · 2025Article
- One Assay, Nine Targets: Advancing Viral Surveillance with Multiplex RT-ddPCR.Analytical chemistry · 2025Article
- Review
- Development of a direct whole genome sequencing for hepatitis A virus from serum and analysis of genetic characteristics.Scientific reports · 2025Article
- Comparative evaluation of four commercial analyzers for the serological screening of hepatitis A.Virology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis A is a vaccine-preventable infection caused by the hepatitis A virus (HAV). Over 150 million new infections of hepatitis A occur annually. HAV causes an acute inflammatory reaction in the liver that usually resolves spontaneously without chronic sequelae. However, up to 20% of patients experience a prolonged or relapsed course and <1% experience acute liver failure. Host factors, such as immunological status, age, pregnancy and underlying hepatic diseases, can affect the severity of disease. Anti-HAV IgG antibodies produced in response to HAV infection persist for life and protect against re-infection; vaccine-induced antibodies against hepatitis A confer long-term protection. The WHO recommends vaccination for individuals at higher risk of infection and/or severe disease in countries with very low and low hepatitis A virus endemicity, and universal childhood vaccination in intermediate endemicity countries. To date, >25 countries worldwide have implemented such programmes, resulting in a reduction in the incidence of HAV infection. Improving hygiene and sanitation, rapid identification of outbreaks and fast and accurate intervention in outbreak control are essential to reducing HAV transmission.
Indexed as
Identifiers
37770459What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.